BTG3 and Crohn disease: Interestingly, 63.8% of rheumatoid arthritis patients and 49.1% of Crohn's disease patients treated with IFX developed ANA positivity, with anti-dsDNA antibody positivity rates of 13% and 21.5%, respectively [16].